Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.10%
SPX
+0.38%
IXIC
+0.59%
FTSE
-0.47%
N225
-0.34%
AXJO
0.00%
Cashu Logo
⌘K
Log In
HomeWatchlistNewsSignals
Stocks
Health Care
nuvb
Nuvation Bio
NYSE: NUVB
+2.45 (+50.94%)
7.245
USD
At close at Nov 19, 20:43 UTC
Summary
News
Signals
Benchmarks
Financials

Overview

Loading chart...

Key Stats

Market Cap
1.64B
Dividend Yield
0.00%
P/E Ratio
-7.55
EPS
-2.11
Revenue
7.87M
Avg. Volume
7.33M

Recently from Cashu

publisher logo
Cashu

Nuvation Bio Faces Investigation for Alleged Fiduciary Breaches Amid Shareholder Concerns

9 months ago
publisher logo
Cashu

Nuvation Bio Launches Access Program for Taletrectinib in ROS1-Positive Lung Cancer Patients

10 months ago
publisher logo
Cashu

Nuvation Bio Launches Expanded Access Program for Taletrectinib in ROS1-Positive NSCLC Patients

10 months ago

About

What does NUVB do?
Nuvation Bio, based in San Francisco, develops novel oncology therapies and has 159 employees. Its clinical portfolio includes candidates like taletrectinib and safusidenib, targeting specific cancer mutations.
Sector
💻 Health Care
IPO
CEO
Employees
278
Headquarters
California, USA
Website
http://www.nuvationbio.com
Join our newsletter to keep up to date with us!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.